Mirum Pharmaceuticals IncMIRM
ASignal's systematic analysis rates MIRM as Neutral.
Reflects the latest available analysis · analyzed Sep 1, 2026
The case on MIRM
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (37.9% YoY)
- High gross margin (81.73%) indicating pricing power
- Positive free cash flow ($76.62M)
- Current ratio (2.86x) and quick ratio (2.62x) suggest solid short-term financial health
- MACD histogram improving (positive divergence at -2.94 vs signal -3.33)
- Negative operating cash flow ($-227.27M)
- Negative profit margin (-139.18%) and return on equity (-702.97%)
- Negative EV/EBITDA (-95.19x) and forward P/E (-282.83x) indicate unprofitability
- Price below SMA20 and SMA50, indicating downtrend
- Price momentum slightly negative (-0.028)
See the full verdict on MIRM
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes MIRM
Most investors never get a second opinion, let alone several. ASignal runs MIRM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.